Ohio State Engineering alumnus Michael Triplett is what you would call a serial biotech entrepreneur. Today, he is co-founder and board chair of Armatus Bio as well as co-founder and board member of Clarametyx Biosciences, a startup infectious disease company pursuing novel therapeutics and vaccines for the treatment and prevention of biofilm-related bacterial infections. Not so long ago, he co-founded and served as president and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies. Myonexus was acquired by Sarepta Therapeutics for more than $225 million in April 2019.  Excelling at the interfaces of business and innovation, Michael is passionate about translating world-class science and technology into transformative businesses, products and capabilities that enhance human health, American competitiveness, and economic opportunity. He focuses on life sciences technology ventures, innovation, technology-based economic development, and STEM education for students of all backgrounds.

Views: 11